Arrowhead Pharmaceuticals, Inc.

322 articles with Arrowhead Pharmaceuticals, Inc.

• Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results

  2/7/2019

  Arrowhead Pharmaceuticals Inc. announced financial results for its fiscal 2019 first quarter ended December 31, 2018. The company is hosting a conference call at 4:30 p.m. EST to discuss results.

• Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results

  1/24/2019

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 7, 2019, at 4:30 p.m. EST to discuss its financial results for the fiscal 2019 first quarter ended December 31, 2018.

• Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia

  1/7/2019

  Arrowhead intends to proceed with AROAPOC31001, a Phase 1 single and multiple dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of ARO-APOC3 in adult healthy volunteers, hypertriglyceridemic patients, and patients with familial chylomicronemia syndrome

• Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases

  1/7/2019

  Arrowhead Pharmaceuticals, Inc. announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 (ANGPTL3) being developed for the treatment of dyslipidemias and metabolic diseases.

• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) on December 7, 2018

  12/17/2018

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 7, 2018, the Board of Directors approved "inducement" grants to 3 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules.

• Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results

  12/11/2018

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 fourth quarter and year ended September 30, 2018.

• Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results

  11/27/2018

  Arrowhead Pharmaceuticals Inc. today announced that it will host a webcast and conference call on December 11, 2018, at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2018.

• 

  Two Biotechs and One Medtech Make Deloitte’s Top 10 of the 2018 Fast 500 List

  11/16/2018

  Two pharmaceutical companies and a medtech maker snagged three of the top-10 spots on Deloitte’s 2018 North America Technology Fast 500, a ranking of the fastest-growing North American companies in the fields of technology, life sciences, telecommunications, media and energy.

• Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018

  11/9/2018

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preliminary clinical data from a Phase 1/2 study (AROHBV1001) of ARO-HBV, a third-generation subcutaneously administered RNA interference (RNAi) therapeutic candidate being developed as a potential treatment for patients with chronic hepatitis B virus (HBV) infection.

• Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018

  11/9/2018

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced clinical data from a Phase 1 study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin (AAT) deficiency

• Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences

  11/1/2018

  Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to present at the following upcoming events:

• Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen

  10/31/2018

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the license agreement and research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the stock purchase agreement between Arrowhead and Johnson & Johnson Innovation – JJDC, Inc., (JJDC) have closed,

• Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics

  10/16/2018

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage the Company’s proprietary Targeted RNAi Molecule (TRiM™) platform.

• Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3

  10/15/2018

  — Arrowhead to host R&D Day October 16, 2018 to discuss ARO-ANG3 and its emerging pipeline of RNAi therapeutics

• Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018

  10/11/2018

  Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) will make two late-breaking poster presentations at The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held on November 9-13, 2018, in San Francisco.

• Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen

  10/4/2018

  Upon closing, Arrowhead to receive $250 million, consisting of $175 million upfront payment from Janssen and $75 million equity investment from Johnson & Johnson Innovation – JJDC, Inc.

• 

  Arrowhead Goes All in With J&J to Develop Hep B Drug for $3.7B

  10/4/2018

  Arrowhead announced a deal with Johnson & Johnson that could conceivably be worth over $3.7 billion, with J&J agreeing to pick up a minor stake in the company, including the task of cultivating and promoting its ARO-HBV Hepatitis B drug.

• Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences

  9/25/2018

  Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to present at the following upcoming event

• Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

  9/24/2018

  The R&D Day will feature presentations by Ira Goldberg, M.D. who will discuss the current treatment landscape and unmet medical need for patients with dyslipidemia and hypertriglyceridemia.

• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) on September 14, 2018

  9/21/2018

  Arrowhead Pharmaceuticals Inc. today announced that as an inducement to entering into employment with the Company, on September 14, 2018, the Board of Directors approved "inducement" grants to nine new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules.